Invokana belongs to a newer class of Type 2 diabetes treatments called sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of medication that works by stopping glucose from being reabsorbed into the blood. The FDA warned Invokana can also cause ketoacidosis, a condition that requires hospitalization and can cause fatal swelling of the brain, severe dehydration and coma.
Number of Lawsuits
About 990 in the Invokana MDL; 57 in the Farxiga MDL
Diabetic ketoacidosis, kidney damage and others
Johnson & Johnson’s Janssen Pharmaceuticals subsidiary, Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim and Eli Lilly
Site of the Invokana New Jersey MDL
Clarkson S. Fisher Federal Courthouse, site of the Invokana New Jersey MDL
According to Johnson & Johnson, there are also federal lawsuits over Invokana pending in federal court in California and Missouri. There are also cases in state courts in Pennsylvania, California and New Jersey.
U.S. District Judge Lorna G. Schofield is overseeing a Farxiga MDL in the Southern District of New York. As of Dec. 18, 2017, there were 55 cases pending in the Farxiga MDL.
515 E Las Olas Blvd #120, Fort Lauderdale, FL 33301
Interested In Invokana Leads?
We are open from 9am — 7pm week days.